
Freeze variability, not progress: strengthen your cell therapy supply chain from the start
Episode 197
Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark. 01:07 Meet Dominic Clarke and Cryoport Systems 06:24 Fresh cells versus frozen cells 08:21 Why teams switch to cryopreservation late 12:37 The challenge of variability 16:47 IntegriCell when you already have a process in place 22:17 An argument for cryopreservation based on data 25:56 The future of IntegriCell and Cryoport Systems This episode is brought to you with the support of Cryoport Systems. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Publisher
Beyond Biotech - the podcast from Labiotech
Published
May 15, 2026
Duration
30 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#freezevariability #strengthen #celltherapysupply
